Why Juno Therapeutics Stock Is Blasting Off Today
Shares of Juno Therapeutics (NASDAQ: JUNO) are up by double digits for the second day in a row on extremely heavy volume. The catalyst behind this continued surge higher is the nearly $12 billion buyout of rival adoptive cell therapy company Kite Pharma (NASDAQ: KITE) by Gilead Sciences (NASDAQ: GILD) yesterday.
As of 1:26 p.m. EDT, investors have already bid up Juno's shares by another 18%. If this sizable move northward holds -- and all signs indicate that it will -- Juno's shares will end up gaining 40% in just the first two trading sessions of this week.
Image source: Getty Images.
Source: Fool.com
Gilead Sciences Inc Stock
€115.32
-0.230%
The stock is an absolute favorite of our community with 67 Buy predictions and no Sell predictions.
With a target price of 128 € there is a slightly positive potential of 11.0% for Gilead Sciences Inc compared to the current price of 115.32 €.
